IL-1β and TNFα-initiated IL-6-STAT3 pathway is critical in mediating inflammatory cytokines and RANKL expression in inflammatory arthritis.

Rheumatoid arthritis (RA) is a chronic inflammatory disease that causes irreversible joint damage and significant disability. However, the fundamental mechanisms underlying how inflammation and joint destruction in RA develop and are sustained chronically remain largely unknown. Here, we show that signal transducer and activator of transcription 3 (STAT3) is the key mediator of both chronic inflammation and joint destruction in RA. We found that inflammatory cytokines highly expressed in RA patients, such as IL-1β, tumor necrosis factor alpha and IL-6, activated STAT3 either directly or indirectly and in turn induced expression of IL-6 family cytokines, further activating STAT3 in murine osteoblastic and fibroblastic cells. STAT3 activation also induced expression of receptor activator of nuclear factor kappa B ligand (RANKL), a cytokine essential for osteoclastogenesis, and STAT3 deficiency or pharmacological inhibition promoted significant reduction in expression of both IL-6 family cytokines and RANKL in vitro. STAT3 inhibition was also effective in treating an RA model, collagen-induced arthritis, in vivo through significant reduction in expression of IL-6 family cytokines and RANKL, inhibiting both inflammation and joint destruction. Leukemia inhibitory factor expression and STAT3 activation by IL-1β were mainly promoted by IL-6 but still induced in IL-6-deficient cells. Thus, our data provide new insight into RA pathogenesis and provide evidence that inflammatory cytokines trigger a cytokine amplification loop via IL-6-STAT3 that promotes sustained inflammation and joint destruction.

[1]  John J. O’Shea,et al.  Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550) , 2011, The Journal of Immunology.

[2]  T. Hirano,et al.  Local microbleeding facilitates IL-6– and IL-17–dependent arthritis in the absence of tissue antigen recognition by activated T cells , 2011, The Journal of experimental medicine.

[3]  M. Kubo,et al.  Effects of a Janus kinase inhibitor, pyridone 6, on airway responses in a murine model of asthma. , 2011, Biochemical and biophysical research communications.

[4]  D. Morris,et al.  Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis , 2010, Journal of Inflammation.

[5]  J. Bland,et al.  META060 inhibits osteoclastogenesis and matrix metalloproteinases in vitro and reduces bone and cartilage degradation in a mouse model of rheumatoid arthritis. , 2010, Arthritis and rheumatism.

[6]  J. Fridman,et al.  Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050 , 2010, The Journal of Immunology.

[7]  Hong Ma,et al.  STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress , 2010, Proceedings of the National Academy of Sciences.

[8]  F. Breedveld,et al.  Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial , 2009, Annals of the rheumatic diseases.

[9]  J. Pike,et al.  A novel distal enhancer mediates cytokine induction of mouse RANKl gene expression. , 2009, Molecular endocrinology.

[10]  I. McInnes,et al.  Animal models of rheumatoid arthritis , 2009, European journal of immunology.

[11]  H. Aburatani,et al.  BMP2 Regulates Osterix through Msx2 and Runx2 during Osteoblast Differentiation* , 2008, Journal of Biological Chemistry.

[12]  Toshio Hirano,et al.  Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. , 2008, Immunity.

[13]  L. Audoly,et al.  Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis , 2008, Arthritis research & therapy.

[14]  A. Brasier,et al.  The Functional Role of an Interleukin 6-inducible CDK9·STAT3 Complex in Human γ-Fibrinogen Gene Expression* , 2007, Journal of Biological Chemistry.

[15]  Katsuaki Sato,et al.  Selective Expansion of Foxp3-Positive Regulatory T Cells and Immunosuppression by Suppressors of Cytokine Signaling 3-Deficient Dendritic Cells1 , 2007, The Journal of Immunology.

[16]  P. Emery,et al.  Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders. , 2007, Rheumatology.

[17]  Chen Dong,et al.  STAT3 Regulates Cytokine-mediated Generation of Inflammatory Helper T Cells* , 2007, Journal of Biological Chemistry.

[18]  Kozo Nakamura,et al.  Impaired bone fracture healing in matrix metalloproteinase-13 deficient mice. , 2007, Biochemical and biophysical research communications.

[19]  R. D. Hatton,et al.  Transforming growth factor-β induces development of the TH17 lineage , 2006, Nature.

[20]  P. Miller,et al.  Denosumab in Postmenopausal Women with Low Bone Mineral Density , 2007 .

[21]  Y. Toyama,et al.  DC-STAMP is essential for cell–cell fusion in osteoclasts and foreign body giant cells , 2005, The Journal of experimental medicine.

[22]  T. Kishimoto Interleukin-6: from basic science to medicine--40 years in immunology. , 2005, Annual review of immunology.

[23]  T. Mcclanahan,et al.  Divergent Pro- and Antiinflammatory Roles for IL-23 and IL-12 in Joint Autoimmune Inflammation , 2003, The Journal of experimental medicine.

[24]  J. O’Shea,et al.  Prevention of Organ Allograft Rejection by a Specific Janus Kinase 3 Inhibitor , 2003, Science.

[25]  R. Kitazawa,et al.  Vitamin D3 supports osteoclastogenesis via functional vitamin D response element of human RANKL gene promoter , 2003, Journal of cellular biochemistry.

[26]  R. Price,et al.  Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. , 2002, Arthritis and rheumatism.

[27]  Lionel B Ivashkiv,et al.  Rheumatoid Arthritis Synoviocyte Survival Is Dependent on Stat31 , 2002, The Journal of Immunology.

[28]  Y. Saeki,et al.  A Point Mutation of Tyr-759 in Interleukin 6 Family Cytokine Receptor Subunit gp130 Causes Autoimmune Arthritis , 2002, The Journal of experimental medicine.

[29]  Takafumi Yoshida,et al.  Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. , 2001, The Journal of clinical investigation.

[30]  D. Männel,et al.  A Novel p75TNF Receptor Isoform Mediating NFκB Activation* , 2001, The Journal of Biological Chemistry.

[31]  Y. Toyama,et al.  Macrophage- and neutrophil- dominant arthritis in human IL-1α transgenic mice , 2001 .

[32]  G. Stark,et al.  IL-1-induced NFκB and c-Jun N-terminal kinase (JNK) activation diverge at IL-1 receptor-associated kinase (IRAK) , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[33]  T. Suda,et al.  An adherent condition is required for formation of multinuclear osteoclasts in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor κB ligand , 2000 .

[34]  K. Hirokawa,et al.  Adenoviral Transfer of Cyclin-Dependent Kinase Inhibitor Genes Suppresses Collagen-Induced Arthritis in Mice1 , 2000, The Journal of Immunology.

[35]  H. Genant,et al.  A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. , 2000, Arthritis and rheumatism.

[36]  S. Morham,et al.  Prostaglandin G/H synthase-2 is required for maximal formation of osteoclast-like cells in culture. , 2000, The Journal of clinical investigation.

[37]  C. O’Brien,et al.  STAT3 Activation in Stromal/Osteoblastic Cells Is Required for Induction of the Receptor Activator of NF-κB Ligand and Stimulation of Osteoclastogenesis by gp130-utilizing Cytokines or Interleukin-1 but Not 1,25-Dihydroxyvitamin D3 or Parathyroid Hormone* , 1999, The Journal of Biological Chemistry.

[38]  S. Morony,et al.  OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.

[39]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[40]  C. Gabay,et al.  Interleukin-1 receptor antagonist: role in biology. , 1998, Annual review of immunology.

[41]  J. Darnell STATs and gene regulation. , 1997, Science.

[42]  S. Akira,et al.  Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[43]  E. Sercarz,et al.  Inactivation of T cell receptor peptide-specific CD4 regulatory T cells induces chronic experimental autoimmune encephalomyelitis (EAE) , 1996, The Journal of experimental medicine.

[44]  J. Woody,et al.  Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis , 1994, The Lancet.

[45]  D. Kioussis,et al.  Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. , 1991, The EMBO journal.

[46]  D. Woolley,et al.  Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. , 1984, Arthritis and rheumatism.

[47]  M. Dallman,et al.  Immunisation against heterologous type II collagen induces arthritis in mice , 1980, Nature.

[48]  A. Kang,et al.  Autoimmunity to type II collagen an experimental model of arthritis , 1977, The Journal of experimental medicine.